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Abstract: Genome-wide association studies show strong evidence of association with endometriosis for markers on 
chromosome 1p36 spanning the potential candidate genes WNT4, CDC42 and LINC00339. WNT4 is involved in 
development of the uterus, and the expression of CDC42 and LINC00339 are altered in women with endometriosis. 
We conducted fine mapping to examine the role of coding variants in WNT4 and CDC42 and determine the key SNPs 
with strongest evidence of association in this region. We identified rare coding variants in WNT4 and CDC42 pres-
ent only in endometriosis cases. The frequencies were low and cannot account for the common signal associated 
with increased risk of endometriosis. Genotypes for five common SNPs in the region of chromosome 1p36 show 
stronger association signals when compared with rs7521902 reported in published genome scans. Of these, three 
SNPs rs12404660, rs3820282, and rs55938609 were located in DNA sequences with potential functional roles 
including overlap with transcription factor binding sites for FOXA1, FOXA2, ESR1, and ESR2. Functional studies will 
be required to identify the gene or genes implicated in endometriosis risk. 
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Introduction
Large gene mapping studies in endometriosis 
have consistently identified strong association 
with disease risk for markers in the region close 
to wingless-type MMTV integration site family, 
member 4 (WNT4) on chromosome 1 [1-4]. The 
single nucleotide marker with the strongest sig-
nal rs7521902 identified in the original studies 
[1, 2] is located approximately 20 kb upstream 
from the transcription start site for WNT4. This 
is an interesting region as rs7521902 is also 
implicated in risk for ovarian cancer [5], bone 
mineral density and risk of fracture [6]. 
Subsequent studies in endometriosis cases 
and controls re-analysed data for a higher den-
sity of SNPs across this region with genotypes 
estimated by imputation [3, 4]. Results provide 
strong evidence for replication of association in 
the region of WNT4 with the highest signals 
located within the WNT4 genomic sequence. 
However, the region of strong association 
extends across adjacent genes and spans the 
region including the long intergenic non-protein 
coding RNA LINC00339, cell division cycle 42 
(CDC42) and WNT4 [3, 4].
WNT4 is a strong candidate for functional 
changes increasing risk for endometriosis and 
ovarian cancer. Expression of WNT4 is critical 
for development of the female reproductive 
tract [7, 8]. WNT4 and other WNT family mem-
bers are expressed in human endometrium dur-
ing both the proliferative and secretory phases 
[9] and expression is up-regulated by oestrogen 
in an oestrogen receptor independent manner 
[10]. However, adjacent genes within the DNA 
block showing association include CDC42 and 
LINC00339, both implicated in endometriosis. 
CDC42 is a small GTPase of the Rho-subfamily, 
which regulates signalling pathways that con-
trol diverse cellular functions including cell mor-
phology, migration, endocytosis and cell cycle 
progression. The gene is expressed in the endo-
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metrium and is reported to be differentially 
expressed in endometriosis [11]. LINC00339 
(also known as HSPC157) is differentially 
expressed in endometriosis lesions versus 
autologous uterine endometrium [12]. Both 
CDC42 and LINC00339 must also be consid-
ered as candidates for the action of genetic 
variants on endometriosis risk.
Effects of individual SNPs on disease risk are 
small and determining the specific genes and 
pathways affecting disease risk is the best 
approach to understand mechanisms leading 
to endometriosis. The aims of this study were to 
genotype SNPs in the exons of WNT4 and 
CDC42 to determine whether the association 
signal could be explained by coding variants, 
and to genotype common non-coding variants 
previously implicated from imputed data to 
confirm results for the best SNPs located in the 
region of WNT4. We also conducted in silico 
analyses to evaluate possible functional roles 
of our top 50 non-coding variants across the 
region.
Materials and methods
The coding regions of WNT4 were screened for 
variants in 100 unrelated individuals chosen 
from 100 case-dense families drawn from the 
QIMR Berghofer Medical Research Institute 
dataset [13]. They include 15 families with at 
least four affected sisters, 71 families with 
three affected sisters and 14 families with at 
least two sisters and two other relatives diag-
nosed with endometriosis. Cases for genotyp-
ing were one sample per family chosen as the 
case with the most severe stage of disease in 
each family.
Coding variants were genotyped in samples 
from 958 endometriosis cases with a family 
history drawn from our Australian study of 
endometriosis [13, 14]. All cases had surgically 
confirmed endometriosis and disease severity 
including four-stages (I-IV) was assessed using 
the revised American Fertility Society (rAFS) 
classification system [15]. The control group 
included 959 unrelated controls drawn from 
women recruited for a study of twins who self-
reported that they had never been diagnosed 
with endometriosis [14]. After removing indi-
viduals in case families with non-Caucasian 
ancestry revealed by our GWA studies [16], 930 
cases and 959 controls were included in our 
analyses. 
Ethical approvals
Study protocols were reviewed and approved by 
the QIMR Human Research Ethics Committee. 
Participation was voluntary and each partici-
pant gave written informed consent. 
High Resolution Melt (HRM) assay and se-
quencing
We screened for coding variants in the exons of 
WNT4 in DNA from 100 endometriosis cases 
using a High Resolution Melting (HRM) tech-
nique [17]. WNT4 PCR primers were designed 
to amplify the 5’ and 3’UTRs, non-coding and 
coding exons, including at least 50 bp of intron-
ic sequence either side of each exon to cover 
intron-exon boundaries using the Primer 3.0 
program [18]. PCR products were screened on 
a Rotor-Gene 6000 Real-time Rotary Analyser 
(Corbett Research, QIAGEN, Hilden, Germany). 
Melting curves were analysed using the Rotor-
Gene 6000 analysis software v 1.7 (Corbett 
Research). Samples showing patterns different 
from wild-type were sequenced using BigDye 
3.0 terminator chemistry (Applied Biosystems).
We also searched for coding variants in both 
WNT4 and CDC42 using public databases with 
results from extensive exome sequencing 
including dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/), 1000 Genomes (http://brow- 
ser.1000genomes.org/), the NHLBI GO Exome 
Sequencing Project (ESP, http://evs.gs.wash-
ington.edu/EVS/), and the exome chip genotyp-
ing array design (http://genome.sph.umich.
edu/wiki/Exome_Chip_Design). 
Genotyping
Twenty seven coding variants in WNT4, five cod-
ing and four potential functional variants (locat-
ed in the promoter area and splice sites) in 
CDC42, and six key imputed SNPs identified 
from the GWA studies [3] were genotyped using 
Sequenom MassARRAY technology in the 930 
cases and 959 controls. Genotyping assays 
were designed using standard procedures and 
SNPs were typed using iPLEX™ chemistry on a 
MALDI-TOF Mass Spectrometer (Sequenom 
Inc., San Diego, CA, USA) [14].
Data analysis
PLINK software was used to analyse SNP data 
for quality control measures and to test for 
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Table 1. Variants identified in WNT4 during re-sequencing of 100 endometriosis cases including the minor allele frequencies (MAF) observed in 
public databases and in the cases
SNP name Location (Hg19) Role Nucleotide variant Amino acid change MAF MAF in 100 cases sequenced Functional changes predicted
rs115547783 22456050 Intronic c.236 + 59C/G 0.008# 0.015
Novel* 22456184 Exonic c.161C/T p.Tyr80His Not_obs 0.005 No
rs34228276 22446768 Exonic c.243A/G p.Pro277Pro 0.025# 0.015
Novel 22446536 3’UTR c.473 T/-in-del Not_obs 0.005 micRNA binding sites
#Minor allele frequency (MAF) estimate from phase 1 data from the 1000 Genome Project. *This variant was novel at the time of sequencing, but subsequently reported by Exome. 
Sequencing Project (ESP) (release ESP6500 data_20 June 2012). Not_obs: Polymorphisms were not observed.
Table 2. Results for tests of association for WNT4 and CDC42 variants genotyped in 930 endometriosis cases and 959 controls
Variants Nucleotide variant Role MAF in cases MAF in controls P value OR Functional prediction*
WNT4 variants
In-del novel variant T/-in-del 3’UTR 0.001 0 0.242 NA micRNA binding sites
Exon 2 novel variant c.161C/T Non-synonymous 0.001 0 0.489 NA No damage prediction
rs12067696 A/G Synonymous 0.001 0 0.492 NA Splicing (ESE & abolish domain)
Conservation: +++
rs34228276 A/G Synonymous 0.018 0.023 0.302 0.78 (0.50-1.23) Conservation: +++
rs115547783 C/G Intronic 0.016 0.015 0.894 1.07 (0.64-1.81) NA
CDC42 variants
rs191653816 C/T promoter 0.001 0 0.492 NA TF binding sites
rs16860621 A/G promoter 0.125 0.130 0.708 0.96 (0.79-1.17) TF binding sites
rs17837976 C/T Intronic, splice site 0.002 0.005 0.180 0.41 (0.13-1.32) Conservation: +++
*Functional prediction using: miRBase and MicroInspector program for micRNA binding site prediction, SIFT and Polyphen program for amino acid change prediction, HaploReg 
program for TF binding site prediction and ‘snp funtion prediction’ program.
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association between SNPs and endometriosis 
risk. Call rates were all greater than 95% and all 
SNPs were in Hardy-Weinberg equilibrium (P > 
0.05). Association tests for endometriosis risk 
were performed in PLINK using the standard 
chi-square (--assoc) test for common variants 
and Fisher’s exact (--fisher) test for low frequen-
cy variants [19]. 
To assess the combined contribution of multi-
ple rare variants towards endometriosis risk, 
multiple logistic regression was performed. 
Briefly, genotypes for each SNP were re-coded 
to allele dosages using PLINK’s --recodeA 
option (i.e., additive recoding of the number of 
minor alleles). Multiple logistic regression anal-
ysis using the glm function in the R statistical 
package [20] compared the model with multi-
ple SNPs to the model with zero SNPs to pro-
vide a multiple degree of freedom test for 
association.
Bioinformatics analysis
We performed bioinformatic analyses on a 150 
Kb region of chromosome 1 across the CDC42 
and WNT4 genes. Linkage disequilibrium (LD) 
between SNPs and the presence of haplotype 
blocks was determined using the Haploview 
program [21]. Potential effects of non-synony-
mous (coding) variants were predicted using 
the Sorting Intolerant from Tolerant (SIFT) pro-
gram [22, 23] Polyphen [24], the PANTHER 
PSEC classification system [25] and the predic-
tion of pathological mutations program (PMut) 
[26]. SNPs in the 3’UTR were screened for their 
potential to change microRNA binding sites 
using the miRBase [27, 28], miRDB [29], and 
MicroInspector databases [30].
High throughput functional assays have been 
conducted by the international ENCODE project 
to identify functional regions of the genome 
outside of gene coding regions. The ENCODE 
data includes areas of open chromatin identi-
fied using DNaseI hypersensitivity (HS), For- 
maldehyde-Assisted Isolation of Regulatory 
Elements (FAIRE), and Chromatin immunopre-
cipitation (ChIP) experiments and the locations 
of functional regulatory elements including pro-
moters, enhancers, silencers, insulators, locus 
control regions and novel elements [31-33]. 
Several programs are available to search the 
ENCODE data. We used HaploReg version 1 
[34] to search for SNPs with functional annota-
tions in high LD (r2 > 0.8) to our most strongly 
associated SNPs and the RegulomeDB pro-
gram [35] to rank potential functional roles for 
SNPs based on their location across the entire 
150 Kb region. The scoring system for Regu- 
lomeDB ranges from 1-6 with the strongest evi-
dence for functional roles as scores 1 (a-f). A 
score of 2 includes evidence of transcription 
factor (TF) binding and DNase footprint signals. 
Scores of 1 require additional evidence of eff- 
ects of the SNP on specific gene expression. 
Results
Search for rare and novel variants in WNT4 
Five coding exons (exons 1-5), the 5’ and 
3’UTRs, and the intron/exon boundaries for 
WNT4 were screened by HRM assay. Four vari-
ants were detected amongst 100 endometrio-
sis cases using HRM including two known vari-
ants and two novel variants (Table 1). One SNP 
rs34228276 is a synonymous A to G change 
coding for the amino acid proline at position 
277 and was seen at a similar frequency in con-
trols (Table 2). The other one, rs115547783 is 
in intron 2. A novel non-synonymous T to C 
change in exon 2 was predicted to change an 
amino acid from tyrosine to histidine at position 
80 (p.Tyr80His). This was detected in one endo-
metriosis patient in heterozygous form. The 
second novel variant was an insertion of a T 
base in the non-coding region of the 3’UTR (six 
base pairs downstream of the termination 
codon) and found in another patient in hetero-
zygous form (Table 1). All members of both 
families for whom DNA samples were available, 
including the proband individuals, were then 
screened via HRM and/or sequencing for the 
presence of the relevant variants. The exon 2 
variant was observed in two affected sisters 
and the father of the proband, but an affected 
aunt did not carry the variant (Figure 1A). The 
3’UTR insertion/deletion (in-del) T in the sec-
ond family was present in all available affected 
sisters and their father (Figure 1B). These vari-
ants were not detected in other cases or in any 
control samples by Sequenom genotyping 
(Table 2).
Both novel variants were examined for poten-
tial functional effects in silico. There was no 
predicted effect of the p.Tyr80His substitution 
in exon 2 (corresponding to the variant 
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rs115547783) using the Polyphen and SIFT 
programs and the PANTHER PSEC classifica-
tion system. The novel in-del variant located in 
the 3’UTR is predicted to be in a binding site of 
microRNA-4767-5p (miRBase) and was predict-
ed to change a binding site from hsa-miR-3151 
to hsa-miR-4507 by MicroInspector (Table 2).
Genotyping known coding variants in WNT4 
and CDC42
We genotyped 36 coding variants in WNT4 and 
CDC42 documented in public databases (Table 
3), in addition to the novel variants identified by 
HRM. Genotyping of these variants in our set of 
930 endometriosis cases and 959 controls 
revealed only 3 of 27 WNT4 variants and 3 of 9 
variants in CDC42 were polymorphic in our 
sample (Tables 2 and 3, Figures 2 and 3). Two 
variants, rs12067696 in WNT4 and 
rs191653816 in CDC42, were found only in 
cases and not in controls, although the differ-
ences in allele frequencies were not significant 
(P = 0.492). Frequencies for these variants 
were <0.001 and they were not observed in the 
100 cases screened by HRM. The WNT4 syn-
onymous variant rs12067696 is conserved 
through mammalian and vertebrate species 
and predicted to be an exonic splicing enhanc-
er (ESE) by the SNP Function Prediction 
(FuncPred) program. The SNP rs191653816 in 
the CDC42 promoter was located in the binding 
sites of 22 TFs by HaploReg (Table 2). 
There was no evidence that individual coding 
variants contributed to endometriosis risk, but 
several rare variants were detected only in 
cases. We therefore analysed data for the six 
variants listed in Table 2 using multiple logistic 
regression and found no significant evidence 
for combined effects on association with endo-
metriosis risk (x62 = 6.973; P = 0.323).
Common variants in WNT4 
We previously reported significant association 
across the CDC42-WNT4 region with the stron-
gest signal from genotypes estimated by impu-
tation. To confirm imputation results we geno-
typed the five top imputed SNPs together with 
rs7521902, the top SNP from the original GWA 
studies, in our 930 cases and 959 controls. 
Our genotyping results showed high concor-
dance between genotyped and imputed data 
(98-100%) and confirmed stronger evidence for 
association with SNPs located in intron 1 of 
WNT4 (Table 4) than for rs7521902 located 
~20 kb upstream of WNT4.
The five SNPs are in high LD and together the 
risk alleles form a single risk haplotype (P = 7 
x10-4) with a similar estimate for disease risk as 
the individual SNPs. 
Functional annotation for WNT4 common vari-
ants
Functional annotation of our top SNPs revealed 
limited evidence for a functional role for the 
sentinel SNP rs61768001 (defined as the SNP 
with best association signal in a multi-SNP 
analysis) or for the original genotyped SNP 
rs7521902. Analysis of 50 SNPs (with stron-
gest evidence of association from the GWAS 
data) across the 150 Kb region using 
RegulomeDB identified seven variants in strong 
LD (r2 > 0.8) with rs61768001 and two SNPs in 
high LD with rs7521902 with evidence of pre-
dicted functional roles (Table 5, Figures 3 and 
4I). The SNP with the best score (2b) was 
rs12404660 (r2 = 0.84 with rs61768001; 
Table 5, Figure 4II and 4III). SNP rs12404660 
is located in an area of histone protein 
H3K4me1 chromatin modification associated 
with transcription enhancer sequences, open 
chromatin, altered regulatory motifs for the 
transcription factor YY1 and a binding site for 
the transcription factor CTCF, all of which are 
suggestive of regulatory potential. Two addi-
tional SNPs may also have functional roles as 
predicted by the HaploReg, and JASPAR core 
programs. SNP rs3820282, located in intron 1 
of WNT4, (r2 = 0.94 to rs61768001), is predict-
ed to lie in a conserved region within regulatory 
Figure 1. Pedigrees of endometriosis cases carrying 
novel variants in the WNT4 gene: (A) Pedigree of the 
endometriosis family with a novel non-synonymous 
variant in exon 2 (p.Tyr80His) and (B) Pedigree of an 
endometriosis family with a novel insertion/deletion 
variant in 3’UTR (in-del T). The proband individual 
screened by HRM is marked with an asterisk. 
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motifs bound by the transcription factors oes-
trogen receptor 1 (ESR1) and oestrogen recep-
tor 2 (ESR2). No TF binding sites were predicted 
at the original G allele of this variant. However, 
the change to the minor A allele introduced 
potential regulatory sites for ESR1 and ESR2 
identified by HaploReg and JASPAR (Figure 4III, 
Table 5). The SNP rs55938609, in high LD with 
rs61768001 (r2 = 0.98, Figure 5), is located in 
a region of histone protein H3K4Me2 modifica-
Table 3. Known coding variants in WNT4 and CDC42 identified from dbSNP, 1000 Genomes (1000G), 
Exome Sequencing Project (ESP), Exome Chips manifest (EC), and COSMIC project
Gene Variants Location  (Hg19) Source Role MAF
Nucleotide 
variant
Amino acid  
change
WNT4 rs112942159 22446645 dbSNP, 1000G Synonymous Not_obs T/C p.318Ala/Ala
WNT4 rs112452625 22446690 dbSNP, 1000G Synonymous 0.003# A/G p.303Ile/Ile
WNT4 rs145169034 22446782 dbSNP, 1000G Synonymous 0.001# G/A p.273Leu/Leu
WNT4 rs201963772 22446798 ESP5400 release Non-synonymous Not_obs T/A p.267Asp/Glu
WNT4 rs140080433 22446860 dbSNP, 1000G Non-synonymous Not_obs A/G p.247Arg/Cys
WNT4 rs41441349 22446902 dbSNP, 1000G Non-synonymous 0.002# A/G p.233Ala/Thr
WNT4 rs140262773 22446925 dbSNP, 1000G Non-synonymous Not_obs A/G p.225Pro/Leu
WNT4 rs193047338 22446929 dbSNP, 1000G Non-synonymous 0.001# T/C p.224Val/Met
WNT4 rs121908650 22446952 dbSNP, 1000G Non-synonymous Not_obs G/A p.216Glu/Gly
WNT4 rs138491414 22447774 dbSNP, 1000G Non-synonymous Not_obs G/C p.173Arg/Pro
WNT4 rs12067696 22447821 dbSNP, 1000G Synonymous 0.017# A/G p.157Asp/Asp
WNT4 rs139165736 22447940 dbSNP, 1000G Non-synonymous 0.002# C/T p.148Gln/Arg
WNT4 rs121908651 22448042 dbSNP, 1000G Non-synonymous Not_obs T/C p.114Ala/Val
WNT4 rs139045509 22448044 dbSNP, 1000G Synonymous Not_obs A/G p.113Tyr/Tyr
WNT4 rs16826648 22456146 dbSNP, 1000G Synonymous 0.010# A/G p.92Leu/Leu
WNT4 rs121908652 22456175 dbSNP, 1000G Non-synonymous Not_obs T/C p.83Arg/Trp
WNT4 rs34611251 22456205 dbSNP, 1000G Frame shift Not_obs G/- p.73Leu/Trp
WNT4 rs144407094 22456326 dbSNP, 1000G Synonymous 0.001# T/C p.32Ser/Ser
WNT4 rs121908653 22469381 dbSNP, 1000G Non-synonymous Not_obs C/T p.12Leu/Pro
WNT4 unknown 22446572 ESP Non-synonymous 0.0001§ A/G p.343Trp/Arg
WNT4 unknown 22446857 ESP Non-synonymous 0.0002§ A/G p.248Cys/Arg
WNT4 unknown 22446859 ESP Non-synonymous 0.0001§ T/C p.247His/Arg
WNT4 unknown 22447712 ESP Non-synonymous 0.0001§ T/C p.194Ser/Gly
WNT4 unknown 22456127 ESP Non-synonymous 0.0001§ T/C p.99Ser/Gly
WNT4 unknown 22456174 ESP Non-synonymous 0.0001§ T/C p.83Gln/Arg
WNT4 unknown 22446566 EC Non-synonymous 0.0007§ G/C
WNT4 unknown 22446856 EC Non-synonymous 0.0003§ T/C
CDC42 unknown 22412982 ESP Non-synonymous 0.0001§ C/G p.77Leu/Val
CDC42 COSM46468 22405060 1000G, COSMIC Non-synonymous Not_obs T/C p.30Ser/Leu
CDC42 rs142108830 22413282 ESP, dbSNP Non-synonymous Not_obs G/A p.137Ile/Val
CDC42 COSM260019 22417991 COSMIC Non-synonymous Not_obs A/G p.557Arg/His
CDC42 COSM229859 22405006 COSMIC Non-synonymous Not_obs T/G p.12Gly/Val
CDC42 rs16860621 22379360 dbSNP, 1000G promoter 0.146# A/G
CDC42 rs16860623 22379375 dbSNP, 1000G promoter Not_obs T/G
CDC42 rs191653816 22379314 dbSNP, 1000G promoter 0.001# T/C
CDC42 rs17837976 22408212 dbSNP, 1000G Intron, splice site 0.014# C/T
§MAF estimate from Exome Sequencing Project. #MAF estimate from phase 1 data from 1000 Genomes. COSMIC, Catalogue of 
Somatic Mutations in Cancer.
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tion, associated with both promoters and enh- 
ancers (Figure 4III), and potential binding sites 
for the transcription factors forkhead box A1 
(FOXA1) and A2 (FOXA2) (Figure 4III, Table 5). 
Discussion
GWAS for endometriosis report strong associa-
tions for disease risk with markers at chromo-
some 1p36, a region which spans potential 
candidate genes WNT4, CDC42 and LINC00339 
[1-4]. To further investigate the WNT4 locus we 
first sequenced the WNT4 coding regions and 
identified two novel variants. One variant was a 
non-synonymous variant coding for an amino 
acid substitution p.Tyr80His with no predicted 
deleterious effect from in silico analysis. The 
second variant was a 3’UTR insertion/deletion 
predicted to be in a micro-RNA binding site for 
miR-4767-5p and to change a binding site for 
miR-3151, associated with melanoma [36] and 
childhood acute lymphoblastic leukemia [37]. 
Both novel variants were seen only in the fami-
lies in which they were first detected. 
During the project, data on coding variants 
from sequencing ~12,000 individuals were 
released from the Exome Sequencing Project 
(ESP6500 data, Jun 2012) reducing the need 
for further sequencing. For example the exome 
data included our novel p.Tyr80His variant 
(rs115547783) with a minor allele frequency 
(MAF) of 0.00012 in the European American 
population. Genotyping all coding variants in 
Figure 2. Rare coding variants in WNT4 identified by High Resolution Melt analysis or from public databases and 
genotyped in 930 cases and 959 controls.
Figure 3. Rare coding variants in CDC42 identified by High Resolution Melt analysis or from public databases and 
genotyped in 930 cases and 959 controls.
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Table 4. Results for association tests for imputed common variants in WNT4 genotyped in 930 endometriosis cases and 959 controls
Variants Location (Hg19) Role N_variant MAF MAF in cases MAF in controls P value OR
rs61768001 22465820 Intron 1-2 C/T 0.234# 0.202 0.156 2.002 x10-4 1.38 (1.16-1.63)
rs12037376 22462111 Intron 1-2 A/G 0.224# 0.201 0.156 2.735 x10-4 1.37 (1.15-1.61)
rs56318008 22470407 Promoter T/C 0.220# 0.190 0.147 3.860 x10-4 1.36 (1.15-1.62)
rs55938609 22470451 Promoter C/G 0.230# 0.190 0.148 4.730 x10-4 1.36 (1.14-1.61)
rs7412010 22436446 3’ near gene C/G 0.186* 0.203 0.160 7.696 x10-4 1.33 (1.13-1.57)
rs7521902 22490724 Genomic A/C 0.235* 0.267 0.241 0.067 1.15 (0.99-1.33)
*MAF estimate from HapMap CEU population (HapMap data release 28; phase 1, 2 & 3; August 10). #MAF estimate from phase 1 data from 1000 Genomes.
Table 5. Functional regulation annotation for common SNPs in high LD (r2 ≥ 0.8) with rs61768001 and rs7521902 using HaploReg and Regu-
lomeDB
Variants Location (hg19) SNP score* Cons DNAseI HS peak (N) TFs binding Motifs changed Gene Genomic position
Common SNPs in high LD with rs61768001
rs12038474 22403357 - SEF-1 CDC42 intronic 
rs7412010 22436446 - HES1 7.4 kb 3’ of WNT4 intergenic
rs12404660 22458794 2b 45 CTCF YY1# WNT4 intronic
rs12037376 22462111 5 6 SEF-1, WNT4 intronic
rs61768001 22465820 5 9 Gabpa# WNT4 intronic
rs3820282 22468215 5 +++ 33 Esr2, Esr1 WNT4 intronic
rs56318008 22470407 5 34 Gfi1b 887 bp 5’ of WNT4 promoter
rs55938609 22470451 4 31 FOXA1, FOXA2 931 bp 5’ of WNT4 promoter
Common SNPs in high LD with rs7521902
rs72478520 22489567 4 11 IKZF1# 20 kb 5’ of WNT4 intergenic
rs7521902 22490724 5 1 20 kb 5’ of WNT4 intergenic
rs3920498 22492887 5 5 Smad3, TP53# 23 kb 5’ of WNT4 Intergenic
*Scores from RegulomeDB. Prediction for SNP with score = 2b: TF binding + any motif + DNase Footprint + DNase peak. Prediction for SNP with score = 4: TF binding and DNase 
peak. Prediction for SNP with score = 5: TF binding or DNase peak. #Identified by various methods in a number of cell types (http://regulome.stanford.edu/). N is number of cell 
types in which DNase peaks marked.
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WNT4 and CDC42 reported in public databases 
identified only 6 variants that were polymorphic 
in our sample. Two of these variants were rare, 
had predicted functional effects and were 
found only in cases. Tested either individually 
or together, the six rare variants did not provide 
Figure 4. ENCODE annotation of WNT4 GWA and imputed variants in endometriosis. (I) Overview of the region of 
chromosome 1 including the CDC42 and WNT4 genes. Genotyped markers are shown by vertical lines with results 
(log-10 P values) for all endometriosis cases in black and stage B endometriosis cases in brown. Peaks for histone 
modification marks included in the ENCODE data [39] are shown for H3K4Me1 on 7 cell types (Tier 1 and Tier 2). 
The ENCODE data also shows areas of open chromatin as revealed by DNaseI, FAIRE and ChIP experiments in Tier 
1 and Tier 2 cell types indicated by solid blocks (Regions showing peaks defined by both DNase I and FAIRE assays 
are in black, highly significant regions with combinations of peaks from these assays are in blue. Less significant 
regions identified by only DNase I HS as peaks are in green). The peak signals of open chromatin by FAIRE for normal 
endometrial tissue are shown in the Endometrium FAIRE Pk track. (II) Regions of interest around nine imputed SNPs. 
Three SNPs with the strongest association signals are located in regions of open chromatin as shown by DNaseI 
signals in the ENCODE data. (III) A zoomed-in image for the three top SNPs; (A) rs12404660, (B) rs3820282, and 
(C) rs55938609 (purple vertical lines) and functional annotation by ENCODE. Regulatory protein bound regions and 
histone modifications indicated by ChIP-seq of H3K4m2 in a subset of Tier 1 and 2 cell types (in greyscale light (low-
est) to dark (highest)). The level of conservation across the region is shown for mammals. (A) SNP rs12404660 lies 
in histone modification area for H3K4Me1, open chromatin location by DNaseI, FAIRE, and ChIP assays, transcrip-
tion factors CTCF by ChIP and sequence motifs of transcription factor YY1 by footprinting assays (B) rs3820282 is 
located within sequence motifs for transcription factors ESR1 and ESR2 and (C) rs55938609 lies within sequence 
bound by the transcription factors FOXA1 and FOXA2.
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evidence for association with disease risk in 
our case-control sample. Our results demon-
strate no evidence that rare exonic or promoter 
region variants in WNT4 or CDC42 were associ-
ated with disease risk. 
Our case-control sample for this study has only 
80% power to detect a genotype relative risk 
(GRR) of 1.4 at an allele frequency of 0.25 [14] 
and very low power to identify association with 
rare SNPs with low MAF unless the GRR was 
much greater (e.g. a GRR of at least 1.7 at an 
allele frequency of 0.05 is required for 80% 
power [14]). We chose familial cases for initial 
genotyping because the frequencies of alleles 
contributing to disease are generally enriched 
in these designs [38]. We have a further 4000 
cases available for genotyping to increase 
power, but concluded that while effects of 
some rare variants contributing to disease risk 
in carriers cannot be excluded, the evidence 
did not justify further genotyping. All coding 
variants were rare and the association signal in 
this region cannot be explained by coding vari-
ants in either WNT4 or CDC42. 
Analysis with imputed SNPs previously report-
ed genome-wide significant association for a 
number of common SNPs close to WNT4 and 
CDC42 [3]. Genotyping key common SNPs 
demonstrated strong concordance (>98%) 
between observed and imputed genotypes and 
confirmed previous suggestions that the 
strongest association signals lie in the 
non-coding regions around WNT4. 
Haplotype analyses of our common SNPs 
spanning the region show a single com-
mon risk haplotype and this result sug-
gests the observed association signal at 
this locus is not being driven by a rare 
causal variant in either the coding or non-
coding regions. The association signal is 
most likely due to functional effects of one 
or more of the common non-coding SNPs 
in this haplotype block. 
Up to 88% of variants associated with 
common diseases are found within introns 
and intergenic regions [39] and it is likely 
that causal variants function by altering 
gene regulation. To annotate potential 
functional roles of our top variants, we 
screened 50 SNPs with the lowest P val-
ues from imputed data [3]. Three variants, 
rs12404660, rs3820282, and rs55938- 
609, all in high LD with our top SNP 
Figure 5. Linkage disequilibrium (r2) between genotyped and 
imputed common variants across the region of WNT4 and 
CDC42. 
rs61768001, had the best evidence for poten-
tial functional effects in the ENCODE data as 
identified by the HaploReg and RegulomeDB 
programs [35]. All three variants are located in 
validated and significant regions of open chro-
matin with combinations of DNaseI HS and 
FAIRE peaks in multiple cell types (Figure 4III) 
[39]. The three variants were also located in 
binding sites for TFs or altered regulatory 
motifs. SNP rs12404660 is located at a bind-
ing site for the transcription factor CTCF, and 
the regulatory motif for YY1, TFs which function 
as enhancer blockers, transcriptional repres-
sors and activators, and initiators of transcrip-
tion [40-43]. 
SNP rs55938609 is located at a predicted TF 
binding site for FOXA1 in T-47D cells and FOXA2 
in HepG2 cells in the ENCODE data. FOXA1 
mediates oestrogen receptor (ER) function and 
is a critical factor for interactions between ER 
and chromatin [44]. FOXA1 and H3K4me2 
interact at enhancers to increase gene tran-
scription [45]. The minor A allele at rs3820282 
may alter regulatory motifs for oestrogen recep-
tor (ESR1) identified in various cell types by 
footprinting experiments [35] and ESR2 [34]. 
ESR1 and ESR2 are involved in differentiation 
and proliferation of cells in target tissues 
including ovaries, uterus, and mammary gland 
[46-48]. Regulatory elements at these sites 
WNT4 region and endometriosis risk
203 Int J Mol Epidemiol Genet 2013;4(4):193-206
occur in multiple cell types, but functional stud-
ies of potential regulatory sites must be carried 
out in relevant target tissues to determine any 
role in endometriosis risk. 
In conclusion, we identified coding variants in 
WNT4 and CDC42 present only in women with 
endometriosis, but these variants were rare 
and there was no evidence for association with 
increased disease risk. Genotyping key com-
mon non-coding variants confirmed imputation 
results showing a strong association signal cov-
ering the chromosome region that includes 
LINC00339, CDC42 and WNT4. The strong 
association signal is not explained by coding 
variants in WNT4 or CDC42 and our genetic 
data cannot determine which of the genes in 
this region are affected. Functional studies on 
gene expression and gene regulation in rele-
vant target tissues will be necessary to identify 
the gene or genes responsible for increased 
endometriosis risk. SNPs located in sites with 
potential functional roles in binding of tran-
scription factors FOXA1, FOXA2, ESR1 and 
ESR2 indicate potential targets to prioritise for 
future functional experiments to understand 
the molecular pathophysiology of endome- 
triosis.
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